Advancing the frontiers of cancer diagnostics: Post-ASCO wit...

Post-ASCO 2025, Eric Matthews, chief business officer at Caris Life Sciences, discusses advancing the frontier of cancer diagnostics and treatment.

Putting patients and their families first: Dr Corina Dutcus,...

Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, discusses the data Eisai presented at ASCO 2025.

Enhancing anti-tumour activity: A post-ASCO conversation wit...

Following science to fruition, putting patients first: An AS...

At ASCO25, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial. Alison Dziarmaga discussed the data with pharmaphorum.

Johnson & Johnson, ASCO 2025: Redefining global cancer care

Mark Wildgust, VP of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, discusses J&J’s ambition to get in front of cancer.